Ondine Biomedical treats first patients in nasal photodisinfection US Phase 2 trial for the prevention of post-operative infections
February 07, 2022 02:15 ET | Ondine Biomedical Inc.
Vancouver, Canada, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare system tens of billions of...
Photodisinfection technology could be a game-changer in fight against antimicrobial resistance
January 21, 2022 05:00 ET | Ondine Biomedical Inc.
Vancouver, Canada, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ondine Biomedical’s photodisinfection technology is one of the only new technologies available to economically combat drug-resistant...
Ondine Biomedical appoints Charles Young to lead sales and marketing activity in North America
January 05, 2022 11:01 ET | Ondine Biomedical Inc.
Vancouver, Canada, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Ondine Biomedical Inc. (LON:OBI) has appointed Charles Young as its VP Sales & Marketing, North America to lead the commercialization of its...
Ondine Biomedical appoints Professor Trevor Jones to lead COVID-19 advisory board
December 15, 2021 05:00 ET | Ondine Biomedical Inc.
Vancouver, Canada, Dec. 15, 2021 (GLOBE NEWSWIRE) -- AIM listed life sciences company, Ondine Biomedical, has appointed Professor Trevor Jones CBE FMedSci to lead a new advisory board on the use of...